• Explore /
  • Poster
  • / SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).

SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).

Abstract Video & Slides Poster

Authors

Antoine Hollebecque

Antoine Hollebecque

Institut Gustave Roussy, Villejuif, France

Antoine Hollebecque , Juanita Suzanne Lopez , Sarina A. Piha-Paul , Afshin Dowlati , Amita Patnaik , Vladimir Galvao , Bruno Bockorny , Kartik Sehgal , Ed Kingsley , Rachel E. Sanborn , Cesar Augusto Perez , Solange Peters , Mingjin Yan , Natalya N. Nazarenko , Emiliano Calvo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT04389632

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3024)

DOI

10.1200/JCO.2023.41.16_suppl.3024

Abstract #

3024

Poster Bd #

222

Abstract Disclosures

Similar Posters

First Author: Amita Patnaik

First Author: Charu Aggarwal

First Author: Jordi Rodon Ahnert

First Author: Gary K. Schwartz